Infinitus Systems vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI voice automation platform handling healthcare phone calls — benefits verification, prior auth, and referrals — at scale. San Francisco CA; raised $52M+ (a16z, GV);
About
Infinitus Systems is a healthcare AI company that automates the high-volume, repetitive phone call work that burdens provider administrative teams. Founded in 2019 and headquartered in San Francisco, California, Infinitus has raised more than $52 million from investors including Andreessen Horowitz and GV. The company's AI voice agent, called Maya, conducts real-time phone conversations with insurance payers to verify benefits, check prior authorization status, confirm referrals, and gather other eligibility information on behalf of healthcare providers.\n\nTraditionally, benefits verification and prior authorization follow-up requires large teams of staff members spending hours on hold and navigating complex phone trees. Infinitus replaces this manual process with an AI agent that operates around the clock, completing calls faster than human agents and capturing structured data directly into provider workflows. Customers include health systems, specialty practices, revenue cycle management outsourcers, and digital health companies that need to scale patient access operations without proportionally growing headcount.\n\nThe platform is designed for interoperability, delivering results through APIs and direct integrations with EHR systems, practice management software, and RCM platforms. Infinitus has processed tens of millions of healthcare transactions and continues to expand the scope of calls its AI can handle, with a roadmap that includes scheduling, referral coordination, and patient-facing outreach.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.